Olpasiran

Eli Lilly's muvalaplin, an oral drug, significantly reduced lipoprotein(a) (Lp(a)) levels in a Phase II study, meeting the primary endpoint.

Zerlasiran, a siRNA therapy, demonstrated an 85% reduction in Lp(a) levels over 36 weeks in the ALPACAR-360 trial, showing promise for ASCVD patients.

Muvalaplin, an oral drug by Eli Lilly, significantly reduced lipoprotein(a) (Lp(a)) levels in a Phase 2 trial, offering a potential non-injectable treatment option.

Olpasiran significantly reduces lipoprotein(a) (Lp(a)) levels by over 95% in patients with atherosclerotic cardiovascular disease, marking a potential breakthrough in managing this potent risk factor.

David Baker, Demis Hassabis, and John Jumper won the Nobel Prize in chemistry for computational protein design and AlphaFold's protein structure prediction, potentially improving drug design.